v3.26.1
Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Noncontrolling Interest
Beginning Balance at Dec. 31, 2024 $ 202,485 $ 14 $ 1,506,353 $ 166 $ (1,303,824) $ (224)
Beginning Balance, Shares at Dec. 31, 2024   147,773,744        
Issuance of common stock for cash upon exercise of stock options 5,451 $ 1 5,450      
Issuance of common stock for cash upon exercise of stock options, Shares   882,493        
Vesting of restricted stock units and market-based restricted stock units   3,260,485        
Share-based compensation expense 12,147   12,147      
Other comprehensive loss (32)     (32)    
Net (loss) income (29,830)       (29,852) 22
Ending Balance at Mar. 31, 2025 190,221 $ 15 1,523,950 134 (1,333,676) (202)
Ending Balance, Shares at Mar. 31, 2025   151,916,722        
Beginning Balance at Dec. 31, 2025 225,001 $ 15 1,581,848 253 (1,363,323) 6,208
Beginning Balance, Shares at Dec. 31, 2025   153,779,418        
Issuance of common stock for cash upon exercise of stock options $ 5,133 $ 1 5,132      
Issuance of common stock for cash upon exercise of stock options, Shares 655,786 655,786        
Vesting of restricted stock units and market-based restricted stock units   5,262,017        
Share-based compensation expense $ 11,928   11,928      
Capital contributions for Digital Biotechnologies, Inc. 2,475   800     1,675
Other comprehensive loss (281)     (281)    
Net (loss) income (20,015)       (20,033) 18
Ending Balance at Mar. 31, 2026 $ 224,241 $ 16 $ 1,599,708 $ (28) $ (1,383,356) $ 7,901
Ending Balance, Shares at Mar. 31, 2026   159,697,221